Heba W. Alhamdia,
Mohammad Y. Alfaifibc,
Ali A. Shatibc,
Serag Eldin I. Elbehairibcd,
Mohammed Er-rajye,
Reda F. M. Elshaarawy*f,
Yasser A. Hassangh and
Rozan Zakryai
aCollege of Sciences, Biology Department, King Khalid University, Abha 61413, Saudi Arabia
bKing Khalid University, Faculty of Science, Biology Department, Abha 9004, Saudi Arabia
cTissue Culture and Cancer Biology Research Laboratory, King Khalid University, Abha, 9004, Saudi Arabia
dCell Culture Lab, Egyptian Organization for Biological Products and Vaccines (VACSERA Holding Company), 51 Wezaret El-Zeraa St., Agouza, Giza, Egypt
eLIMAS Laboratory, Faculty of Sciences Dhar El Mahraz, Sidi Mohamed Ben Abdellah University, Fez, Morocco
fDepartment of Chemistry, Faculty of Science, Suez University, 43533 Suez, Egypt. E-mail: reda.elshaarawy@suezuniv.edu.eg
gCollege of Pharmacy, Al-Kitab University, Kirkuk 36015, Iraq
hDepartment of Pharmaceutics, Faculty of Pharmacy, Delta University for Science and Technology, Gamasa, Egypt
iChemistry Department, Faculty of Science, Port-Said University, Port-Said, Egypt. E-mail: rzakrya@yahoo.com
First published on 19th September 2024
Correction for ‘New multifunctional hybrids as modulators of apoptosis markers and topoisomerase II in breast cancer therapy: synthesis, characterization, and in vitro and in silico studies’ by Heba W. Alhamdi et al., RSC Adv., 2024, 14, 28555–28568, https://doi.org/10.1039/D4RA04219K.
The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers.
This journal is © The Royal Society of Chemistry 2024 |